Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07424430

Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Diabetes (DM) Body Weight Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity (Disorder) Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Type 2 Diabetes

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

T2D Cohort:

  • A clinical diagnosis of T2D ≥ 1 year
  • HbA1c ≥ 6.5% (pre-index date)
  • Initiated semaglutide or other AHA(s) before January 1st, 2023*
  • Seen by an LMC endocrinologist in the last 18 months as of the query date
  • ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
  • Informed data consent for their medical record data to be used for research purposes

Obesity Cohort:

  • 18 years or older
  • BMI ≥ 27 kg/m2
  • HbA1c < 6.5% (pre-index date)
  • Initiated semaglutide before January 1st, 2023*
  • Seen by an LMC endocrinologist in the last 18 months as of the query date
  • ≥ one HbA1c value up to 6 months (± 90 days) prior to index date
  • Informed data consent for their medical record data to be used for research purposes

Exclusion criteria

  • Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA)
  • Clinical diagnosis of T2D (obesity cohort only)
  • Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period
  • Documented history or family history of medullary thyroid carcinoma
  • Participation in a research study with an Investigational Product
  • eGFR < 15 mL/min/1.73m2 at index date
  • Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)
  • Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)

Treatment and study plan

Semaglutide (SEMA)

Drug

participants who initiate semaglutide

Primary outcomes

  1. Change in HbA1c- 3 Years

    Time frame: Baseline to 3 Years

    The primary outcome measure is investigating the change in HbA1c from baseline to 3 years (± 90 days) among adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs

Secondary outcomes

  1. Change in HbA1c- 1 Year

    Time frame: Baseline to 1 year

    Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  2. Change in HbA1c- 2 Years

    Time frame: Baseline to 2 Years

    Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  3. Proportion of individuals who achieve HbA1c ≤ 7.0% - 1 Year

    Time frame: Baseline to 1 Year

    comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  4. Proportion of individuals who achieve HbA1c ≤ 7.0%- 2 Years

    Time frame: Baseline to 2 Years

    comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  5. Proportion of individuals who achieve HbA1c ≤ 7.0% - 3 Years

    Time frame: Baseline to 3 Years

    comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  6. Change in body weight- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  7. Change in body weight- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  8. Change in body weight- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  9. Percent body weight loss ≥ 5% - 1 Year

    Time frame: Baseline to 1 Year

    comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  10. Percent body weight loss ≥ 5% - 2 Years

    Time frame: Baseline to 2 Years

    comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  11. Percent body weight loss ≥ 5% - 3 Years

    Time frame: Baseline to 3 Years

    comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  12. Percent body weight loss ≥ 10% - 1 Year

    Time frame: Baseline to 1 Year

    comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  13. Percent body weight loss ≥ 10% - 2 Years

    Time frame: Baseline to 2 Years

    comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  14. Percent body weight loss ≥ 10% - 3 Years

    Time frame: Baseline to 3 Years

    comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  15. Percent body weight loss ≥ 15% - 1 Year

    Time frame: Baseline to 1 Year

    comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  16. Percent body weight loss ≥ 15%- 2 Years

    Time frame: Baseline to 2 Years

    comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  17. Percent body weight loss ≥ 15%- 3 Years

    Time frame: Baseline to 3 Years

    comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  18. Change in BMI- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  19. Change in BMI- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  20. Change in BMI- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  21. Change in Waist Circumference- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  22. Change in Waist Circumference- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  23. Change in Waist Circumference- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  24. Change in Blood Pressure- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  25. Change in Blood Pressure- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  26. Change in Blood Pressure- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 year in the kidney, liver and cardiovascular sub-cohorts

  27. Change in eGFR- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in eGFR (ml/min1.73m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  28. Change in eGFR- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in eGFR (ml/min1.73m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  29. Change in eGFR- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in eGFR (ml/min1.73m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  30. Proportion of individuals with ≥ 50% decline in eGFR- 1 Year

    Time frame: Baseline to 1 Year

    comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  31. Proportion of individuals with ≥ 50% decline in eGFR- 2 Years

    Time frame: Baseline to 2 Years

    comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  32. Proportion of individuals with ≥ 50% decline in eGFR- 3 Years

    Time frame: Baseline to 3 Years

    comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  33. Change in uACR- 1 year

    Time frame: Baseline to 1 Year

    comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  34. Change in uACR- 2 years

    Time frame: Baseline to 2 Years

    comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  35. Change in uACR- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  36. Change in ALT- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  37. Change in ALT- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  38. Change in ALT- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  39. Change in Lipids- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  40. Change in Lipids- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  41. Change in Lipids- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  42. Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  43. Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  44. Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  45. Number of non-semaglutide GLP-1-based therapies- 1 Year

    Time frame: Baseline to 1 Year

    comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  46. Number of non-semaglutide GLP-1-based therapies- 2 Years

    Time frame: Baseline to 2 Years

    comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  47. Number of non-semaglutide GLP-1-based therapies- 3 Years

    Time frame: Baseline to 3 Years

    comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  48. Change in insulin use- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  49. Change in Insulin- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  50. Change in Insulin- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  51. Change in TDD of insulin- 1 Year

    Time frame: Baseline to 1 Year

    comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

  52. Change in TDD of insulin- 2 Years

    Time frame: Baseline to 2 Years

    comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

  53. Change in TDD of insulin- 3 Years

    Time frame: Baseline to 3 Years

    comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

  54. Incidence of non-acetylsalicylic acid antiplatelet use

    Time frame: Baseline to Endpoint

    comparing the incidence of non-acetylsalicylic acid antiplatelet use between adults with T2D treated with 1 or more years of semaglutide and adults with T2D treated with 1 or more years of other AHAs in the cardiovascular sub-cohort

  55. Percent body weight loss ≥ 5%

    Time frame: Baseline to 1 Year

    Comparing the percent body weight loss ≥ 5% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  56. Percent body weight loss ≥ 10%

    Time frame: Baseline to 1 Year

    Comparing the percent body weight loss ≥ 10% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  57. Percent body weight loss ≥ 15%

    Time frame: Baseline to 1 Year

    Comparing the percent body weight loss ≥ 15% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  58. Body Weight

    Time frame: Baseline to 1 Year

    Comparing body weight (kg) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  59. BMI

    Time frame: Baseline to 1 Year

    Comparing BMI (km/m^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  60. Waist Circumference

    Time frame: Baseline to 1 Year

    Comparing the waist circumference (cm) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  61. HbA1c

    Time frame: Baseline to 1 Year

    Comparing HbA1c (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  62. Percent of new onset pre-diabetes

    Time frame: Baseline to 1 Year

    Comparing the percent of new onset pre-diabetes (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  63. Percent of new onset T2D

    Time frame: Baseline to 1 Year

    Comparing the percent of new onset T2D (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  64. Blood Pressure

    Time frame: Baseline to 1 Year

    Comparing blood pressure in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  65. eGFR

    Time frame: Baseline to 1 year

    Comparing eGFR (ml/min1.73m^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  66. uACR

    Time frame: Baseline to 1 Year

    Comparing uACR (mg/mmol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  67. ALT

    Time frame: Baseline to 1 Year

    Comparing ALT (U/L) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

  68. Lipids

    Time frame: Baseline to 1 Year

    Comparing lipids (triglycerides, LDL-C, HDL-C , total cholesterol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

Other outcomes

  1. HbA1c

    Time frame: Baseline to Endpoint (3 Years)

    Comparing HbA1c between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  2. Proportion of individuals who achieve HbA1c ≤ 7.0%

    Time frame: Baseline to Endpoint (3 Years)

    Comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  3. Body Weight

    Time frame: Baseline to Endpoint (3 Years)

    Comparing body weight (kg) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  4. Percent body weight loss ≥ 5%

    Time frame: Baseline to Endpoint (3 Years)

    Comparing percent body weight loss ≥ 5% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  5. Percent body weight loss ≥ 10%

    Time frame: Baseline to Endpoint (3 Years)

    Comparing percent body weight loss ≥ 10% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  6. Percent body weight loss ≥ 15%

    Time frame: Baseline to Endpoint (3 Years)

    Comparing percent body weight loss ≥ 15% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  7. BMI

    Time frame: Baseline to Endpoint (3 Years)

    Comparing BMI (kg/m^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  8. eGFR

    Time frame: Baseline to Endpoint (3 Years)

    Comparing eGFR (ml/min1.73m^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  9. Proportion of individuals with ≥ 50% decline in eGFR

    Time frame: Baseline to Endpoint (3 Years)

    Comparing the proportion of individuals with ≥ 50% decline in eGFR between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  10. uACR

    Time frame: Baseline to Endpoint (3 Years)

    Comparing uACR (mg/mmol) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

  11. ALT

    Time frame: Baseline to Endpoint (3 Years)

    Comparing ALT (U/L) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

Study contacts

Contact information is provided by the study sponsor or research team.

Lisa Chu, PhD

CONTACT

[email protected]

(416) 645-2929

giovana Romero, Msc

CONTACT

[email protected]

(416) 645-2929

Sponsors and collaborators

Lead sponsor

LMC Diabetes & Endocrinology Ltd.

Other

Registry information

Acronym: SEMA-CKM

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 20, 2026
Registry last updated
Feb 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.